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Microangiopathic hemolytic anemia (MAHA) occurs occasionally as a paraneoplastic syndrome in some solid tumors, but MAHA 
accompanied by signet ring cell carcinoma of an unknown origin is very rare. In this study, we present the case of an 80-yr-old man 
who was admitted to the hospital because of a 1-month history of lower back pain and dyspnea. He was diagnosed with MAHA on 
the basis of the laboratory findings that revealed anemia with schistocytes, decreased haptoglobin levels, and a negative direct 
Coombs’ test. Bone marrow examination, which was performed because of the progression of anemia, revealed  bone marrow 
metastases of signet ring cell carcinoma with extensive bone marrow necrosis. However, the primary origin of this signet ring cell 
carcinoma was not found. When the cause of progressive MAHA is unknown, the possibility of cancer-associated MAHA must be   
excluded by performing additional tumor workup, including the detection of tumor markers, gastric and colorectal endoscopic 
examinations, bone marrow examinations, and positron emission tomography-computed tomography or bone scans.
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INTRODUCTION
In 1962, Brain et al. [1] coined the term microangiopathic 
hemolytic anemia (MAHA) for characterizing hemolytic 
anemia with fragmented red blood cells in the peripheral 
blood smears. Subsequently, many studies have elucidated 
the pathogenesis and common causes of MAHA [2-7]. One 
of the common causes of MAHA is cancer, particularly gas-
tric, breast, and lung cancers [2-7]. Thus far, only a few 
cases of MAHA associated with signet ring cell carcinoma 
(SRCC) of unknown origin have been reported [8, 9]. 
In this report, we describe an 80-yr-old patient who pre-
sented with MAHA due to metastatic SRCC of unknown 
origin.
CASE REPORT
An 80-yr-old man was admitted to the hospital for poor 
oral intake, back pain, dyspnea, and a 1-month history of 
jaundice. The patient was diagnosed with MAHA on the 
basis of the laboratory findings, which showed anemia with 
schistocytes and polychromasia, nucleated red blood cells 
on the blood smear (Fig. 1), decreased haptoglobin levels 
(1.2 mg/dL), a negative direct Coombs’ test, and elevated se-
rum levels of total bilirubin (7.38 mg/dL), lactate dehydro-
genase (LDH) (1,849 IU/L), and alkaline phosphatase (ALP) 
(610 IU/L). Among the tumor markers that were assessed, 
carcinoembryonic antigen level was elevated (785.0 ng/mL). 
In order to rule out the possibility of solid tumor origin, en-
doscopic examinations of the upper and lower gastrointesti-
nal tract and abdominal ultrasonography were performed, 
with unremarkable findings. Thoracic, abdominal, and pel-
vic computed tomography also showed unremarkable find-
ings. However, multiple bone metastases in both the pelvic 
bones, humeri, and femora and the sternum were detected 
on positron emission tomography-computed tomography 
(PET-CT). Because of the progression of MAHA, thrombo-
cytopenia, and hyperbilirubinemia, bone marrow examina-
tion was performed. In the bone marrow aspirates, clusters 
of abnormal, large non-hematopoietic cells were observed 158     www.kjlm.org
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(Fig. 1). The bone marrow biopsy sections showed infiltra-
tion of signet ring-shaped atypical large cells with extensive 
bone marrow necrosis (BMN) (Fig. 2). The signet ring cells 
were positive for CK20 stain and negative for CK7 stain, 
and the cytoplasm of these cells was positive for Alcian blue 
stain (Fig. 3). Finally, we diagnosed the patient with SRCC 
of unknown origin because the primary site of SRCC (a 
subtype of adenocarcinoma) could not be confirmed even 
after a thorough examination, which included endoscopic 
examination of the lower and upper gastrointestinal tract 
and ultrasonography of the abdomen.
The patient received red blood cell and platelet transfu-
sion because of the low platelet count (7.8×10
9/L) and low 
hemoglobin level (9.1 g/dL). However, the hemoglobin level 
and platelet count did not increase even after transfusion. 
Persistently high serum levels of bilirubin, LDH, and ALP 
were observed. The patient refused to undergo further 
treatment and was discharged 20 days after admission. He 
died 3 weeks after discharge from the hospital.
DISCUSSION
MAHA can occur as a paraneoplastic syndrome in cancer 
patients, and it may present as the first manifestation of a 
malignant tumor. The most common tumors associated 
with MAHA are gastric, breast, and lung cancers and malig-
nancies of unknown origin [2-7]. A Korean study reported 
that 14 (25.5%) out of 55 MAHA patients had gastric cancer 
[10]. In our patient, MAHA was the initial finding of SRCC 
of unknown origin. 
Fig. 2. (A) Trephine biopsy section reveals clusters of malignant cells with extensive necrosis (center, bone marrow [BM] biopsy section, hematoxylin and eosin 
stain [H&E], ×100). (B) Tumor cells show eccentrically located nuclei and abundant mucinous cytoplasm, consistent with signet ring cell carcinoma (BM biopsy 
section, H&E, ×400).
A B
Fig. 1. (A) Schistocytes, polychromasia, and a nucleated red blood cell (arrow) (peripheral blood smear, hematoxylin and eosin stain, ×1,000); (B) non-hemato-
poietic, large cell clusters are visible (bone marrow aspirate, Wright & Giemsa stain, ×400).
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Cancer-associated MAHA (CA-MAHA) is a rare and fa-
tal complication of malignant tumors. Among patients with 
bone marrow metastases from cancer, MAHA patients have 
a worse prognosis than patients without MAHA [11]. Most 
CA-MAHA patients die within a few weeks after the diag-
nosis [12], and the most common cause of death is infec-
tion [10]. Our patient died 4 weeks after he was diagnosed 
with CA-MAHA. On average, the median time interval be-
tween the initial diagnosis of MAHA and the diagnosis of 
the underlying malignancy is 6 days (range, 2–14 days), and 
bone marrow examinations and bone scans are usually per-
formed to detect CA-MAHA [12]. Our patient was diag-
nosed with CA-MAHA on the basis of the findings of bone 
marrow examination and PET-CT conducted 7 days after 
the diagnosis of MAHA. Many studies have recommended 
a thorough tumor workup, including bone marrow exami-
nation, in cases of progressive MAHA of unknown origin 
[2, 8, 9, 11, 12]. 
Characteristic laboratory findings of CA-MAHA are ane-
mia with schistocytes, thrombocytopenia, leukoerythro-
blastic anemia, decreased haptoglobin levels, and elevated 
serum levels of ALP, LDH, and bilirubin [2, 10, 12]. MAHA 
is also seen in many different diseases such as idiopathic 
thrombotic thrombocytopenic purpura (TTP), dissemi-
nated intravascular coagulation (DIC), hemolytic uremic 
syndrome (HUS), and vasculitis. Patients with these dis-
eases have similar laboratory findings and clinical manifes-
tations; therefore, the detection of the underlying diseases is 
important for appropriate and timely treatment [12]. Bone 
pain and respiratory symptoms are observed more fre-
quently in CA-MAHA than in non-CA-MAHA [12, 13]. 
Our patient experienced bone pain and dyspnea. 
Although several studies have suggested that fibrinoid 
necrosis of the bone marrow and tumor cell emboli of the 
arteries, arterioles, and capillaries are the causes of CA-
MAHA, the pathogenesis of CA-MAHA remains unclear 
[14, 15]. Tumor-derived factors, procoagulants, and some 
anti-cancer drugs are also considered causative agents of 
CA-MAHA [16]. Some studies have reported that a de-
crease in the levels of the von Willebrand factor (vWF)-
cleaving protease, ADAMTS13 plays a role in CA-MAHA 
[12]. We were unable to evaluate the presence of tumor em-
boli of the arteries, ADAMTS13, or tumor necrosis factor 
alpha (TNF-α) in this case because the patient was lost to 
Fig. 3. Results of immunohistochemical analysis and Alcian blue staining. 
Tumor cells are positive for CK20 (A) and negative for CK7 stains (B). (C) Al-
cian blue stain reveals cytoplasmic mucin positivity in the tumor cells.
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follow-up after discharge. 
SRCC is a subtype of mucin-producing adenocarcino-
mas. SRCC can arise from virtually all organs, but the most 
common sites of occurrence are the stomach, breast, and 
colon [17, 18]. Mucin-producing adenocarcinomas and 
SRCC show clinicopathological differences [19-23]. Gastro-
intestinal tract SRCC is more common in the young and in 
males and has a worse prognosis than mucin-producing 
adenocarcinomas. SRCC is frequently complicated by me-
tastases to the regional lymph nodes, peritoneal surfaces, 
ovaries, lungs, and bone marrow. The immunohistochemi-
cal characteristics of SRCC can be used to differentiate the 
primary site of SRCC. Usually, the CK7 negative staining 
and CK20 positive staining patterns of the tumor cells ob-
served in this case are more frequently found in colon 
SRCC patients than in gastric SRCC patients [24]. 
A bone marrow biopsy revealed extensive BMN in our 
patient. BMN is a rare and fatal condition that is defined as 
the necrosis of myeloid tissue and medullary stroma with 
preservation of the bone [25]. The prevalence of BMN dif-
fers according to the population studied and the grading 
scales used, but the prevalence of extensive BMN is usually 
below 0.5% in unselected populations [26, 27]. The preva-
lence of BMN in CA-MAHA is unknown, but approxi-
mately 50% of the BMN cases are accompanied by MAHA 
[17, 18]. Only a few cases of BMN with CA-MAHA have 
been reported [3]. The most common underlying diseases 
in patients with BMN are malignancies, particularly acute 
leukemia and gastric cancer [26-28]. 
There is no definitive treatment of choice for CA-MAHA. 
The low platelet count and hemoglobin level make red 
blood cell and platelet transfusion obligatory. Chemother-
apy is the most reliable treatment of choice for the underly-
ing cancer [3, 9, 11, 28]. 
We reviewed 10 previously reported cases of metastatic 
SRCC that showed MAHA as an initial clinical finding (Ta-
ble 1) [29-33]. The most common origins of SRCC are the 
stomach and unknown origins. All the patients showed 
bone marrow and/or bone metastasis, and therefore, bone 
marrow examination played an important role in the diag-
nosis. The time interval between the diagnosis of CA-
MAHA and death was less than 6 weeks. The presence of 
BMN was not assessed in all the patients. 
In conclusion, MAHA can be seen in different diseases; it 
is observed as a paraneoplastic syndrome in cancers, partic-
ularly gastric cancers. CA-MAHA is usually accompanied 
by multiple bone or bone marrow metastases. Therefore, 
bone marrow examination can be used as a primary diag-
nostic tool to investigate the underlying cancer. The prog-
nosis of patients with CA-MAHA is generally poor, and ad-
equate chemotherapy is the only reliable treatment. Because 
of the high prevalence of gastric cancers in the Korean pop-
ulation, additional tumor workup, including the detection 
of tumor markers, gastric and colorectal endoscopic exami-
nation, bone marrow examination, and PET-CT or bone 
scan are recommended in cases of progressive MAHA of 
unknown origin. 
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Table 1. Clinical features of 10 cases of metastatic signet ring cell carcinoma with microangiopathic hemolytic anemia as an initial clinical finding
Case
No. Age/sex Presenting symptoms Hb
(g/dL)
PLT 
(×10
9/L)
LDH 
(IU/L)
Site of 
metastasis
Method used to
investigate cancer Underlying cancer Clinical 
outcome* Rf
1 62/M Jaundice 10.7 86 1,222 BM, bone (multiple) BM biopsy, endoscopy Gastric cancer 4 weeks [8]
2 58/M Abdominal pain, jaundice 7.8 80 833 Bone (multiple) Bone scan, BM biopsy Unknown origin N/A [8]
3 45/M Lower back pain, melena 5.9 50 N/A BM, bone (multiple) BM biopsy, endoscopy Gastric cancer 1 week [29]
4 32/F Fever 6.0 8 N/A BM, bone (multiple) BM biopsy, endoscopy, CT Gastric cancer N/A [29]
5 50/M Lower back pain, chest pain N/A N/A N/A BM BM biopsy, ultrasonography Gastrointestinal tract 6 days [30]
6 57/F Lower back pain N/A N/A N/A BM BM biopsy, bone scan, CT Unknown origin 38 days [30]
7 83/M Weight loss, nausea, vomiting N/A N/A N/A BM BM biopsy, endoscopy, CT Gastric cancer 1 month [30]
8 60/M Fatigue, bone pain in the hip 5.2 111 519 BM BM biopsy, laparotomy Ovarian cancer N/A [31]
9 56/M Fatigue 5.7 30 500 BM BM biopsy, endoscopy Gastric cancer 12 days [32]
10 51/M Fatigue 4.7 40 1,164 BM, bone (multiple) BM biopsy, endoscopy, CT Unknown origin 9 months [33]
*Time interval between the diagnosis of underlying cancer and death.
Abbreviations: PLT, platelet; LDH, lactate dehydrogenase; Rf, reference; N/A, not available; BM, bone marrow; CT, computed tomography.Shin S-Y, et al.  •  A Case of Metastatic Signet Ring Cell Carcinoma of Unknown Origin
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